Document is current
Any future updates will be listed below
-
Authors
Streicher, Nicholas
Amass, Leslie
Wang, Rong
Stephens, Jennifer M.
LeMasters, Traci
Raina, Rutika
Merrill, Emma
Sheikh, Farooq H.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05139680 at ClinicalTrials.govDocuments that mention this clinical trial
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy
https://doi.org/10.1007/s40119-024-00362-9
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 17 December 2023
Accepted: 21 February 2024
First Online: 23 March 2024
Declarations
:
: Leslie Amass and Rong Wang are employees of Pfizer Inc. and own Pfizer stock. Jennifer M. Stephens, Traci LeMasters, and Rutika Raina are employees of OPEN Health, a contract research organization that received research funding related to this study. Emma Merrill is a clinical research coordinator affiliated with MedStar Health. Nicholas Streicher and Farooq H. Sheikh are investigators affiliated with MedStar Health/Georgetown University School of Medicine, which received funding from Pfizer to support the research.
: This study was approved by the MedStar Health Research Institute Institutional Review Board (IRB) (IRB ID: STUDY00006170) and granted a waiver from informed consent. The study followed Good Pharmacoepidemiology Practices guidelines and the principles of the Declaration of Helsinki.
